Skip to main content
Premium Trial:

Request an Annual Quote

Sharpless for Acting FDA Commissioner

Norman Sharpless, the director of the National Cancer Institute, is to serve as the acting commissioner of the Food and Drug Administration, the New York Times reports. The current commissioner, Scott Gottlieb, announced last week that he would be stepping down from his post as of next month.

Sharpless was named to head NCI in 2017 and, prior to that, directed the Lineberger Comprehensive Cancer Center University of North Carolina-Chapel Hill. He also co-founded the biopharmaceutical company G1 Therapeutics

"Dr. Sharpless's deep scientific background and expertise will make him a strong leader for FDA," Alex Azar, the secretary of the Department of Health and Human Services, says in a statement, according to the Times.

In a tweet, Gottlieb says he is pleased with the announcement. "Ned is a friend to FDA, a great public health champion, a dedicated physician, and will be warmly welcomed into his new role," he tweeted.

The Times adds that Azar notes that Sharpless's appointment is temporary and that the search for a permanent successor has begun.

The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.